One-third of amenorrheic transmasculine people on testosterone ovulate

Cell Rep Med. 2024 Mar 19;5(3):101440. doi: 10.1016/j.xcrm.2024.101440. Epub 2024 Feb 22.

Abstract

Transmasculine people usually reach amenorrhea within 6 months of adequate testosterone treatment. It is often assumed that no ovulation occurs during amenorrhea. However, in this study, we report recent ovulatory activity in amenorrheic transmasculine people on testosterone therapy at gender-affirming oophorectomy. Histological signs of recent ovulatory activity, including the presence of ovulatory follicles, corpus luteum, and corpus albicans, are observed in 17 of 52 individuals (33%). This is not significantly correlated to the duration, testosterone serum levels, or type of testosterone used. These results suggest that amenorrhea does not equal anovulation in transmasculine people on adequate testosterone therapy, emphasizing the importance of contraception for people who engage in sexual activity that can result in pregnancy.

Keywords: amenorrhea; fertility; ovulation; testosterone; transgender.

MeSH terms

  • Amenorrhea* / drug therapy
  • Female
  • Humans
  • Ovulation
  • Pregnancy
  • Testosterone* / therapeutic use

Substances

  • Testosterone